AMRI Announces Leadership Changes.

ALBANY, N.Y. -- Albany Molecular Research, Inc. (NASDAQ: AMRI) today announced leadership changes, following the restructuring recently announced at its Large Scale Manufacturing facility in Rensselaer, New York.

Steven R. Hagen, Ph.D. has been promoted to vice president for quality and analytical chemistry. In his new role, Dr. Hagen will be responsible for overseeing analytical and quality functions at all of AMRI's facilities. In addition, he will be responsible for the company's regulatory activities, including the company's relationship with the U.S. Food and Drug Administration.

Prior to his promotion, Dr. Hagen was senior director of analytical quality services, where he supervised AMRI's analytical chemistry team, which measures the chemical purity and physical properties of drugs as they move through the drug development and manufacturing process. He joined AMRI in 2005 from his previous position as director of analytical research and development at Pfizer's Global Research and Development Division in Kalamazoo, Michigan. He began his tenure at Pfizer in 1994 as a research scientist. Prior to Pfizer, he was an analytical biochemist with Ribi ImmunoChem Research, Inc.

Dr. Hagen received a B.A. in biology from Lawrence University, as well as a Master's degree in botany and a Ph.D. in biochemistry, both from the University of Idaho.

Separately, Paul F. Vogt, Ph.D. has been promoted to director of manufacturing at AMRI's Rensselaer manufacturing facility. In his new role, he will be responsible for the manufacturing of all bulk chemicals, pharmaceuticals and intermediates at the company's Rensselaer facility. His area of oversight includes all compounds manufactured in Rensselaer for human clinical trials and commercial products.

Dr. Vogt began his career at AMRI in 1997 as a senior research chemist and has since taken on positions of increasing responsibility, culminating with his promotion in 2005 to director of chemical development, where he oversaw the company's fast-growing chemical development activities, including managing customer projects and project teams involved in process research and scale-up activities.

Dr. Vogt received a bachelor's degree in chemistry at Seton Hall University and a Ph.D. in organic chemistry at the University of Notre Dame.

"We are pleased to announce the promotions of Drs. Hagen and Vogt into these leadership roles at AMRI," said AMRI Chairman, CEO and President Thomas E. D'Ambra, Ph.D. "These promotions occur as part of the recently announced restructuring of our large scale manufacturing operations. Steve and Paul each have managed areas of our business that have been bright spots performance-wise in the recent past. I am confident, as they bring their skills to their increased responsibilities, that AMRI has the right people in place to position our manufacturing operations for long term growth and profitability. We are pleased to announce these changes today and wish Steve and Paul best wishes for continued career growth and success."

Albany Molecular Research, Inc. is a global drug discovery company that provides chemistry services to pharmaceutical and biotechnology companies and conducts its own proprietary R&D programs.

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements may be identified by forward-looking words such as "may," "could," "should," "would," "will," "intend," "expect," "anticipate," "believe" and "continue" or similar words. Readers should not place undue reliance on our forward-looking statements. The company's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the company may not be able to predict and may not be within the company's control. Factors that could cause such differences include, but are not limited to the company's ability to attract and retain experienced scientists, trends in pharmaceutical and biotechnology companies outsourcing of chemical research and development, the company's ability to enforce its intellectual property and technology rights, the risks posed by international operations to the company, and the company's ability to effectively manage its growth as well as those factors discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2005 as filed with the Securities and Exchange Commission on March 16, 2006 and the company's other SEC filings. The company does not undertake any duty to and does not intend to update any forward-looking statements contained in this press release after the date of this press release.